跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 35 条关于
“ARID1B”
全部
35
临床试验
23
药物
3
机构
1
资讯
8
11个月前
Foghorn Therapeutics Reports Breakthrough Progress in Selective ARID1B Degrader for Cancer Treatment
去年
Foghorn Therapeutics Advances Oncology Programs Targeting Chromatin Dysregulation
8个月前
Foghorn Therapeutics Secures $50 Million Financing to Advance First-in-Class Cancer Pipeline
10个月前
Foghorn Therapeutics Advances Multi-Target Protein Degrader Pipeline with FHD-909 Phase 1 Trial Progressing
去年
Foghorn Therapeutics Discontinues FHD-286 Development for AML, Prioritizes Other Programs
2年前
NXP800 Receives FDA Orphan Drug Designation for ARID1a-Deficient Ovarian Cancers
去年
Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial
去年
Aridis Pharmaceuticals Announces Asset Sale and Investment Proposal for Key Pipeline Candidates